• Shopping cart is empty.

    The International Society for Aerosols in Medicine

    Federico Lavorini

    Federico Lavorini

    Frederico Lavorini

    Dept. Experimental And Clinical Medicine, University Of Florence  

    Professional qualifications:

    I qualified in medicine at the University of Florence (1991) and trained in respiratory medicine at the Careggi University Hospital (1996). I undertook the PhD in Respiratory Pathophysiology at University of Florence (2000). Current position: Professor and Chair of Respiratory Medicine, Department of Experimental and Clinical Medicine, University of Florence (I), Head of the Respiratory and Intensive Care Unit, Careggi University Hospital, Florence (I) Member of the following scientific societies or research groups: Italian Society of Respiratory Medicine; Aerosol Drug Management Improvement Team (ADMIT), International Society of Aerosol Medicine (ISAM); Respiratory Effectiveness Group (REG); Device Adherence Steering Group (DASG); Aerosol Society UK. Associate Editor of the Clinical Respiratory Journal and of the Multidisciplinary Respiratory Medicine; Review Editor, Frontiers of Physiology, Respiratory Physiology; member of the editorial board of the Journal of Aerosol Medicine and Pulmonary Drug Delivery. Main

    Clinical and research interests

    Diagnostics and therapeutics of inhaled drugs. Evaluation of novel methods to deliver drugs to the lungs in asthma and COPD. Evaluation of the bioequivalence of inhaled products by using pharmacodynamic endpoints. Diagnosis and treatment of intractable cough. Evaluation of cough motor components and sensitivity in patients with respiratory and non-respiratory diseases. Control of breathing and lung function assessment in asthma patients; methods to help patients in the correct use of inhalers


    Clinicians Role in Promoting Adherence to Inhalation Therapy in Patients with COPD


    Poor inhaler technique and nonadherence impair the efficacy of medications for COPD. A range of factors, including age, dexterity, inspiratory capacity, and cognitive ability can impact patients’ ability to use their device. Treatment success can also be influenced by patient preferences and perceptions. Therefore, it is important that clinicians effectively match inhaler devices to individual patients' needs and abilities and empower patients by including them in treatment decisions. General practitioners (GPs) are best placed to address patients' perceptions and attitudes towards therapy, to individualize treatment choice, and to provide tailored education and device training to maximize adherence to treatment. However, GPs are required to have a fully understanding of device characteristics, in addition to knowledge of their patient's characteristics and comorbidities. Following device selection, patient training and education, including a physical demonstration of the device, are key to eliminate any critical errors that may impact on health outcomes. Also pharmacists must be familiar with the device, as they are usually the last healthcare professionals (HCP) to be seen by patients before a device is used. However, device type is often considered of limited importance when prescribing medication for newly diagnosed patients with COPD. Moreover, HCPs did not uniformly view poor device use as a significant barrier to optimal COPD management. Many HCPs are themselves unable to demonstrate correct inhaler technique. Thus, priority must be given to providing effective training for HCPs to enable them to effectively educate their patients. Integral to training for HCPs should be an awareness of common mistakes and reasons for nonadherence, which can serve as a checklist in the provision of patient education.